Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 6

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
)Prepaid expenses and other current assets(741)(796)Other noncurrent assets2,439 (2,133)Accounts payable3,488 5,705 Accrued compensation and other related benefits(7,817)(9,960)Deferred revenue(458)5,832 Accrued expenses and other current liabilities(2,891)(12,127)Operating lease liability(4,986)(5,599)Other noncurrent liabilities1,040 314 Net cash provided by (used in) operating activities52,059 (8,229)Investing activities:Purchases of intangible assets— (1,000)Purchases of property and equipment(3,471)(5,788)Purchases of marketable securities(49,361)— Proceeds from sales of marketable securities— 3,585 Proceeds from maturities of marketable securities50,000 25,782 Net cash provided by (used in) investing activities(2,832)22,579 Financing activities:Issuance of common stock from exercise of stock options and employee stock purchase plan purchases3,944 6,241 Net cash provided by financing activities3,944 6,241 Effect of exchange rates changes on cash, cash equivalents474 (51)Net increase in cash and cash equivalents53,645 20,540 Cash, cash equivalents at beginning of period344,067 359,284 Cash, cash equivalents at end of period$397,712 $379,824 Supplemental disclosures of cash flow information:Cash paid for taxes$1,318 $2,040 Noncash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities$301 $1,452 Right-of-use assets obtained in exchange for new operating lease liabilities$8,307 $— 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

o

1.    Description of Business and Basis of Presentation

Organization and Description of Business10x Genomics, Inc. (the “Company”) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated research solutions include the Company’s Chromium